ArticleScientific reports2026
Naringenin mitigates experimental Trichinella spiralis infection in in vitro and in vivo studies.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trichinellosis is a global public health concern with significant clinical impact. Albendazole (ABZ) is the standard benzimidazole for trichinellosis; however, shortcomings limit its use, necessitating the search for effective natural substitutes. Naringenin (NAG), a natural phytochemical flavanone, has antiparasitic properties against both helminths and protozoa. This study assessed NAG's potential therapeutic impact on experimental trichinellosis via in vitro and in vivo Studies. An in vitro experiment was performed to assess NAG's direct anthelmintic action against adult Trichinella spiralis (T. spiralis) worms. Then, a mouse model of trichinellosis was used to evaluate NAG's effectiveness in reducing worm and larval loads and assessing its influence on related pathological alterations. The adult worm survival demonstrated an evident in vitro anthelmintic effect of both NAG and ABZ, as documented by electron microscopy, in which the treated groups exhibited loss of their typical shape. Moreover, in the in vivo study, all treated groups showed a decrease in the mean adult intestinal worms and muscle larvae, significantly (P < 0.0001) compared with the model group, with the best reduction rates reported in the NAG + ABZ-treated group, which also reported the best histopathological improvement and the highest reduction in NF-κB expression. These findings concluded that NAG could be a promising natural therapeutic and enhancing agent for ABZ in combating trichinellosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.